CureVac N.V.

The momentum for this stock is not very good. CureVac N.V. is not a good value stock. CureVac N.V. is not a good growth stock. CureVac N.V. is a mediocre stock to choose.

News

GSK, CureVac mRNA flu shot reaches late-stage studies

SeekingAlpha.com: All News GSK (GSK) advances its messenger-RNA-based flu vaccine candidate developed with CureVac (CVAC) into late-stage development after positive mid-stage data. Read more here.\n more…

CureVac to present CVGBM glioblastoma cancer vaccine data at ESMO

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Accesswire TUBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ('CureVac'), a global biopharmaceutical company developing a new class of transformative medicines based...\n more…

CureVac (CVAC) Receives a Hold from Deutsche Bank

TipRanks Financial Blog Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on CureVac (CVAC - Research Report) today and set a price target of $3.90. The co...\n more…

CureVac Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St CureVac ( NASDAQ:CVAC ) Second Quarter 2024 Results Key Financial Results Revenue: €14.4m (up 91% from 2Q 2023). Net...\n more…

CVAC Stock Earnings: CureVac Misses EPS, Beats Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCVAC stock results show that CureVac missed analyst estimates for earnings per share but beat on revenue for the second quarter of...\n more…